Aurobindo Pharma Ltd banner

Aurobindo Pharma Ltd
NSE:AUROPHARMA

Watchlist Manager
Aurobindo Pharma Ltd Logo
Aurobindo Pharma Ltd
NSE:AUROPHARMA
Watchlist
Price: 1 229.1 INR 0.29% Market Closed
Market Cap: ₹713.9B

Relative Value

The Relative Value of one AUROPHARMA stock under the Base Case scenario is hidden INR. Compared to the current market price of 1 229.1 INR, Aurobindo Pharma Ltd is hidden .

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

AUROPHARMA Relative Value
HIDDEN
Show
Worst Case
Base Case
Best Case

Multiples Across Competitors

AUROPHARMA Competitors Multiples
Aurobindo Pharma Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
IN
Aurobindo Pharma Ltd
NSE:AUROPHARMA
715.7B INR 2.1 20.3 9.4 12.5
US
Eli Lilly and Co
NYSE:LLY
924.2B USD 14.3 45.1 30.4 32.5
US
Johnson & Johnson
NYSE:JNJ
571.8B USD 6.1 21.4 14.9 18.3
CH
Roche Holding AG
SIX:ROG
271B CHF 4.4 21 12.4 13.9
CH
Novartis AG
SIX:NOVN
236.2B CHF 5.4 21.8 13.5 17.3
UK
AstraZeneca PLC
LSE:AZN
224.8B GBP 5.1 29.5 16.3 23
US
Merck & Co Inc
NYSE:MRK
283.3B USD 4.4 15.6 9.7 11.8
IE
Endo International PLC
LSE:0Y5F
218B USD 94 -74.6 344.9 865
DK
Novo Nordisk A/S
CSE:NOVO B
1.1T DKK 3.6 10.7 8 9.3
US
Pfizer Inc
NYSE:PFE
150.5B USD 2.4 19.5 7.5 10
US
Bristol-Myers Squibb Co
NYSE:BMY
120.4B USD 2.5 17.2 7.2 8.9
P/E Multiple
Earnings Growth PEG
IN
Aurobindo Pharma Ltd
NSE:AUROPHARMA
Average P/E: 22.2
20.3
13%
1.6
US
Eli Lilly and Co
NYSE:LLY
45.1
28%
1.6
US
Johnson & Johnson
NYSE:JNJ
21.4
7%
3.1
CH
Roche Holding AG
SIX:ROG
21
14%
1.5
CH
Novartis AG
SIX:NOVN
21.8
15%
1.5
UK
AstraZeneca PLC
LSE:AZN
29.5
26%
1.1
US
Merck & Co Inc
NYSE:MRK
15.6
14%
1.1
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -74.6 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
10.7
7%
1.5
US
Pfizer Inc
NYSE:PFE
19.5
26%
0.8
US
Bristol-Myers Squibb Co
NYSE:BMY
17.2
17%
1
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
IN
Aurobindo Pharma Ltd
NSE:AUROPHARMA
Average EV/EBITDA: 43.1
9.4
10%
0.9
US
Eli Lilly and Co
NYSE:LLY
30.4
22%
1.4
US
Johnson & Johnson
NYSE:JNJ
14.9
2%
7.4
CH
Roche Holding AG
SIX:ROG
12.4
6%
2.1
CH
Novartis AG
SIX:NOVN
13.5
5%
2.7
UK
AstraZeneca PLC
LSE:AZN
16.3
13%
1.3
US
Merck & Co Inc
NYSE:MRK
9.7
3%
3.2
IE
E
Endo International PLC
LSE:0Y5F
344.9
N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
8
2%
4
US
Pfizer Inc
NYSE:PFE
7.5
-9%
N/A
US
Bristol-Myers Squibb Co
NYSE:BMY
7.2
-10%
N/A
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett